Yoda Pharmaceuticals Inc
Yoda Pharmaceuticals Inc is a pharmaceutical company that develops, manufactures, and markets prescription drugs, primarily in the oncology and specialty therapeutic areas.
Business. Yoda Pharmaceuticals Inc (7829.TWO) is a pharmaceutical company operating within the Healthcare sector, specifically engaged in the research and development of pharmaceutical products. The firm is listed on the Taiwan Premium Exchange (TPEx) under the ticker symbol 7829.TWO. Specific details regarding the company's operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the business is described at the industry level as a participant in the pharmaceuticals and medical research field.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Yoda Pharmaceuticals Inc (7829.TWO) is a pharmaceutical company operating within the Healthcare sector, specifically engaged in the research and development of pharmaceutical products. The firm is listed on the Taiwan Premium Exchange (TPEx) under the ticker symbol 7829.TWO. Specific details regarding the company's operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the business is described at the industry level as a participant in the pharmaceuticals and medical research field.
Yoda Pharmaceuticals Inc has a fully diluted share count of 83,779,018 shares, with no difference between basic and diluted shares outstanding, indicating no dilution risk from stock options or convertible securities. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
Profitability metrics are not available in the current valuation snapshot, and no industry-specific preferred metrics have been provided for comparison. Without access to key financial ratios such as ROIC, EBITDA margins, or net profit margins, it is not possible to assess Yoda Pharmaceuticals Inc's performance relative to industry medians or to evaluate its return on invested capital.
Segment and geographic exposure data are not disclosed in the available financial reports, making it difficult to assess the company's revenue concentration or geographic diversification. The lack of segment reporting limits the ability to evaluate the performance of different product lines or geographic regions.
Growth trajectory data is not available in the current outlook, and no numeric deltas for revenue or earnings are provided. Without historical revenue data or forward-looking guidance, it is not possible to determine the company's growth rate or future performance expectations.
Risk factors include the inability to assess liquidity risk due to missing balance-sheet data and the absence of going-concern language in source documents. Additionally, the company's dilution risk is currently low, as there is no evidence of dilutive instruments or recent equity issuances that would increase the share count.
Recent events and filings have not been disclosed in the available data, and no transcripts or material announcements have been provided. As a result, it is not possible to evaluate the company's recent strategic developments or operational updates.
- Yoda Pharmaceuticals Inc has no dilution risk as basic and diluted shares are equal.
- Liquidity risk could not be assessed due to missing balance-sheet data and no going-concern language.
- Profitability and return metrics are not available for comparison to industry benchmarks.
- Segment and geographic exposure data are not disclosed, limiting visibility into revenue concentration.
- Growth trajectory and future performance expectations are not quantified in the current outlook.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Yoda Pharmaceuticals Inc Market data — financials · 2026-05-27